Cancer Immunology, Immunotherapy

, Volume 56, Issue 5, pp 699–708 | Cite as

Phase II study of interleukin-2 and 13-cis-retinoic acid as maintenance therapy in metastatic colorectal cancer

  • Francesco Recchia
  • Gaetano Saggio
  • Alisia Cesta
  • Giampiero Candeloro
  • Anna Di Blasio
  • Giovanna Amiconi
  • Marco Lombardo
  • Antonio Nuzzo
  • Angelo Lalli
  • Edoardo Alesse
  • Stefano Necozione
  • Silvio Rea
Original Article

Abstract

Purpose

We have previously shown that low-dose interleukin-2 (IL-2) and 13-cis-retinoic acid (13-cis-RA) improved lymphocyte and natural killer (NK) cell count of patients with advanced tumors showing a clinical benefit from chemotherapy. The primary endpoint of this study was to ask whether IL-2 and 13-cis-RA improved (-0%) lymphocyte and NK cell count in patients with metastatic colorectal cancer (MCRC) that had a clinical benefit from induction chemotherapy. Secondary endpoint was the evaluation of toxicity, progression-free survival (PFS), and overall survival (OS).

Patients and methods

Forty patients with MCRC, showing a clinical benefit from chemotherapy, were treated with subcutaneous low-dose IL-2 (1.8 × 106 IU) and oral 13-cis-RA (0.5 mg/kg) in order to maintain responses and improve survival through the increase of lymphocyte and NK cells. The biological parameters and the clinical outcome of these patients were compared with those of a control group of patients (80) with a similar disease status, including clinical benefit from chemotherapy.

Results

The most common adverse events were mild cutaneous skin rash and fever. After 4 months and 2 years of biotherapy, a statistically significant improvement was observed in lymphocyte and number of NK cells with respect to baseline values and to controls. After a median follow-up of 36 months, median PFS was 27.8 months, while median OS was 52.9 months.

Conclusion

These data show that maintenance immunotherapy with low-dose IL-2 and oral 13-cis-RA in patients with MCRC showing a clinical benefit from chemotherapy is feasible, has a low toxicity profile, improves lymphocyte and NK cell count. An improvement in the expected PFS and OS was also observed. A randomized trial is warranted.

Keywords

Maintenance therapy Metastatic colorectal cancer Interleukin-2 13-cis-retinoic acid Lymphocyte Natural killer cells 

References

  1. 1.
    Aass N, De Mulder PH, Mickisch GH, Mulders P, van Oosterom AT, van Poppel H, Fossa SD, de Prijck L, Sylvester RJ (2005) Randomized phase II/III trial of interferon alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951). J Clin Oncol 23:4172–4178CrossRefPubMedGoogle Scholar
  2. 2.
    Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A (2004) Multicenter international study of oxaliplatin/5-fluorouracil/leucovorin in the adjuvant treatment of colon cancer (MOSAIC) investigators. N Engl J Med 350:2343–2351CrossRefPubMedGoogle Scholar
  3. 3.
    Boyle P, Ferlay J (2005) Cancer incidence and mortality in Europe. Ann Oncol 16:481–488CrossRefPubMedGoogle Scholar
  4. 4.
    Brivio F, Lissoni P, Rovelli F, Nespoli A, Uggeri F, Fumagalli L, Gardani G (2002) Effects of IL-2 preoperative immunotherapy on surgery-induced changes in angiogenic regulation and its prevention of VEGF increase and IL-12 decline. Hepatogastroenterology 49:385–387PubMedGoogle Scholar
  5. 5.
    Cascinu S, Graziano F, Valentini M, Catalano V, Giordani P, Staccioli MP, Rossi C, Baldelli AM, Grianti C, Muretto P, Catalano G (2001) Vascular endothelial growth factor expression, S-phase fraction and thymidylate synthase quantitation in node-positive colon cancer: relationships with tumor recurrence and resistance to adjuvant chemotherapy. Ann Oncol 12:239–244CrossRefPubMedGoogle Scholar
  6. 6.
    Cesana GC, Gail DeRaffele G, Cohen S, Moroziewicz D, Mitcham J, Stoutenburg J, Cheung K, Hesdorffer C, Kim-Schulze S, Kaufman HL (2006) Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 24:1169–1177CrossRefPubMedGoogle Scholar
  7. 7.
    Correale P, Cusi MG, Tsang KY, Del Vecchio MT, Marsili S, La Placa M, Intrivici C, Equino A, Micheli L, Nencini C, Ferrari F, Giorni G, Bonmassar E, Guido Francini G (2005) Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. J Clin Oncol 23:8950–8958CrossRefPubMedGoogle Scholar
  8. 8.
    Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345CrossRefPubMedGoogle Scholar
  9. 9.
    Disis ML, Kim Lyerly K (2005) Global role of the immune system in identifying cancer initiation and limiting disease progression. J Clin Oncol 23:8923–8925CrossRefPubMedGoogle Scholar
  10. 10.
    Fox FE, Kubin M, Cassin M, Niu Z, Trinchieri G, Cooper KD, Rook AH (1999) Retinoids synergize with interleukin-2 to augment IFN-gamma and interleukin-12 production by human peripheral blood mononuclear cells. J Interferon Cytokine Res 19:407–415CrossRefPubMedGoogle Scholar
  11. 11.
    Fumagalli LA, Vinke J, Hoff W, Ypma E, Brivio F, Nespoli A (2003) Lymphocyte independently predict overall survival in advanced cancer patients: a biomarker for IL-2 immunotherapy. J Immunother 26:394–402CrossRefPubMedGoogle Scholar
  12. 12.
    Gabrilovich DI, Velders MP, Sotomayor EM, Kast WM (2001) Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J Immunol 166:5398–5406PubMedGoogle Scholar
  13. 13.
    Greco FA, Figlin R, York M, Einhorn L, Schilsky R, Marshall EM, Buys SS, Froimtchuk MJ, Schuller J, Schuchter L, Buyse M, Ritter L, Man A, Yap AK (1996) Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer. J Clin Oncol 14:2674–2681PubMedGoogle Scholar
  14. 14.
    Hengesbach L, Hoag K (2004) Physiological concentrations of retinoic acid favor myeloid dendritic cell development over granulocyte development in cultures of bone marrow cells from mice. J Nutr 134:2653–2659PubMedGoogle Scholar
  15. 15.
    Herberman RB (1985) Design of clinical trials biological response modifiers. Cancer Treat Rep 69:1161–1164PubMedGoogle Scholar
  16. 16.
    Hill M, Norman A, Cunningham D, Findlay M, Nicolson V, Hill A, Iveson A, Evans C, Joffe J, Nicolson M (1995) Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer J Clin Oncol 13:1287–1290Google Scholar
  17. 17.
    Huang B, Pan PY, Li Q, Sato AI, Levy DE, Bromberg J, Divino CM, Chen SH (2006) Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 66:1123–1131CrossRefPubMedGoogle Scholar
  18. 18.
    Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342CrossRefPubMedGoogle Scholar
  19. 19.
    Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481CrossRefGoogle Scholar
  20. 20.
    Kosmidis PA, Tsavaris N, Skarlos D, Theocharis D, Samantas E, Pavlidis N, Briassoulis E, Fountzilas G (1996) Fluorouracil and leucovorin with or without interferon alfa-2b in advanced colorectal cancer: analysis of a prospective randomized phase III trial. Hellenic Cooperative Oncology Group. J Clin Oncol 14:2682–2687PubMedGoogle Scholar
  21. 21.
    Kusmartsev S, Cheng F, Yu B, Nefedova Y, Sotomayor E, Lush R, Gabrilovich D (2003) All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res 63:4441–4449PubMedGoogle Scholar
  22. 22.
    Mancuso P, Burlini A, Pruneri G, Goldhirsch A, Martinelli G, Bertolini F (2001) Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 97:3658–3661CrossRefPubMedGoogle Scholar
  23. 23.
    Maughan TS, James RD, Kerr DJ, Ledermann JA, McArdle C, Seymour MT, Cohen D, Hopwood P, Johnston C, Stephens RJ, British MRC Colorectal Cancer Working Party (2002) Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. Lancet 359:1555–1563CrossRefPubMedGoogle Scholar
  24. 24.
    Motzer RJ, Murphy BA, Bacik J, Schwartz LH, Nanus DM, Mariani T, Loehrer P, Wilding G, Fairclough DL, Cella D, Mazumdar M (2000) Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 18:2972–2980PubMedGoogle Scholar
  25. 25.
    Naumov GN, Bender E, Zurakowski D, Kang SY, Sampson D, Flynn E, Watnick RS, Straume O, Akslen LA, Folkman J, Almog N (2006) A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst 98:316–325PubMedCrossRefGoogle Scholar
  26. 26.
    Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, Meatchi T, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Galon J (2005) Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353:2654–2666CrossRefPubMedGoogle Scholar
  27. 27.
    Recchia F, De Filippis S, Rosselli M, Saggio G, Cesta A, Fumagalli L, Rea S (2001) Phase IB study of subcutaneously administered interleukin-2 in combination with 13-cis retinoic acid as maintenance therapy in advanced cancer. Clin Cancer Res 7:1251–1257PubMedGoogle Scholar
  28. 28.
    Recchia F, De Filippis S, Rosselli M, Saggio G, Fumagalli L, Rea S (2002) Interleukin-2 and 13-cis retinoic acid in the treatment of minimal residual disease: a phase II study. Int J Oncol 20:1275–1282PubMedGoogle Scholar
  29. 29.
    Recchia F, Nuzzo A, Lalli A, Lombardo M, Di Lullo L, Fabiani F, Fanini R, Venturoni L, Torchio P, Peretti G (1996) Randomized trial of 5-fluorouracil and high-dose folinic acid with or without alpha-2b interferon in advanced colorectal cancer. Am J Clin Oncol 19:301–304CrossRefPubMedGoogle Scholar
  30. 30.
    Recchia F, Rea S, Nuzzo A, Lalli A, Di Lullo L, De Filippis S, Saggio G, Biondi E, Massa E, Mantovani G (2004) Oxaliplatin fractionated over two days with bimonthly leucovorin and 5-fluorouracil in metastatic colorectal cancer. Anticancer Res 24:1935–1940PubMedGoogle Scholar
  31. 31.
    Recchia F, Saggio G, Cesta A, Alesse E, Gallo R, Necozione S, Rea S (2005) Phase II randomized study of interleukin-2 with or without 13-cis retinoic acid as maintenance therapy in patients with advanced cancer responsive to chemotherapy. Anticancer Res 25:3149–3157PubMedGoogle Scholar
  32. 32.
    Recchia F, Saggio G, Nuzzo A, Lalli A, Lullo LD, Cesta A, Rea S (2004) Multicentre phase II study of bifractionated CPT-11 with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer pretreated with FOLFOX. Br J Cancer 91:1442–1444PubMedGoogle Scholar
  33. 33.
    Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White DE (1989) Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210:474–484CrossRefPubMedGoogle Scholar
  34. 34.
    Sakaguchi S (2004) Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22:531–562CrossRefPubMedGoogle Scholar
  35. 35.
    Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1–10CrossRefPubMedGoogle Scholar
  36. 36.
    Smith KA (1988) Interleukin-2: inception, impact and implications. Science 240:1169–1176CrossRefPubMedGoogle Scholar
  37. 37.
    Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216CrossRefPubMedGoogle Scholar
  38. 38.
    Thomas R, Malek TR, Bayer AL (2004) Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 4:665–674CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Francesco Recchia
    • 1
    • 2
    • 9
  • Gaetano Saggio
    • 1
  • Alisia Cesta
    • 1
  • Giampiero Candeloro
    • 1
  • Anna Di Blasio
    • 1
  • Giovanna Amiconi
    • 1
  • Marco Lombardo
    • 3
  • Antonio Nuzzo
    • 4
  • Angelo Lalli
    • 5
  • Edoardo Alesse
    • 6
  • Stefano Necozione
    • 7
  • Silvio Rea
    • 2
    • 8
  1. 1.Unità operativa di OncologiaOspedale Civile di AvezzanoAvezzanoItaly
  2. 2.Fondazione “Carlo Ferri”RomaItaly
  3. 3.Unità operativa di OncologiaOspedale Civile di PescaraPescaraItaly
  4. 4.Unità operativa di OncologiaOspedale Civile di LancianoLancianoItaly
  5. 5.Unità operativa di OncologiaOspedale Civile di GiulianovaGiulianovaItaly
  6. 6.Patologia GeneraleUniversità degli Studi de L’AquilaL’AquilaItaly
  7. 7.Epidemiologia ClinicaUniversità degli Studi de L’AquilaL’AquilaItaly
  8. 8.Chirurgia OncologicaUniversità degli Studi de L’AquilaL’AquilaItaly
  9. 9.Luco dei Marsi (AQ)Italy

Personalised recommendations